173 results on '"Kuo, Hann‐Chorng"'
Search Results
2. Lower urinary tract dysfunction in the central nervous system neurogenic bladder and the real-life treatment outcome of botulinum toxin A
3. Urine biomarker could be a useful tool for differential diagnosis of a lower urinary tract dysfunction
4. Cystoscopic characteristic findings of interstitial cystitis and clinical implications
5. Pathophysiology, clinical presentation, and management of ketamine-induced cystitis
6. Treating overactive bladder symptoms after transurethral prostatic surgery for benign prostatic hyperplasia – Which medication to choose?
7. The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis
8. Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients
9. Potential urine and serum biomarkers for patients with overactive bladder and interstitial cystitis/bladder pain syndrome
10. Improvement in autonomic dysreflexia after detrusor onabotulinumtoxinA injections in patients with chronic spinal cord injuries
11. Pathologic mechanism of the therapeutic effect of botulinum toxin A on interstitial cystitis and painful bladder syndrome
12. Do baseline urodynamic parameters affect the treatment outcome after intravesical 100 U onabotulinumtoxinA injection in patients with idiopathic detrusor overactivity?
13. Onabotulinumtoin-A for the treatment of interstitial cystitis refractory to conventional therapy
14. Prevalence and factors associated with overactive bladder and urinary incontinence in community-dwelling Taiwanese
15. Videourodynamic differential diagnosis of voiding dysfunction in Taiwanese women
16. The promise of bladder wall thickness as a useful biomarker for objective diagnosis of lower urinary tract dysfunction
17. Potential urine biomarkers in bladder outlet obstruction-related detrusor underactivity
18. How to choose appropriate medication for overactive bladder: Findings from the largest integrated clinical trial database analysis of mirabegron studies
19. Pathogenesis evidence from human and animal models of detrusor underactivity
20. Effects of different urodynamic characteristics on therapeutic outcomes of overactive bladder medication in a real-life clinical practice
21. Changes of lower urinary tract function after robot-assisted radical prostatectomy: An urodynamic follow-up within 1 year
22. The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis.
23. Nerve Growth Factor Levels are Increased in Urine but Not Urothelium in Patients With Detrusor Overactivity
24. Strong Correlation Between the Overactive Bladder Symptom Score and Urgency Severity Score in Assessment of Patients With Overactive Bladder Syndrome
25. Transabdominal Ultrasound Measurement of Detrusor Wall Thickness in Patients with Overactive Bladder
26. Pathophysiology of Urothelial Dysfunction in Patients with Interstitial Cystitis/Painful Bladder Pain Syndrome: Increased Apoptosis and Decreased Junctional Protein Expression in the Urothelium due to Suburothelial Inflammation
27. Intravesical Botulinum Toxin Injection for Overactive Bladder—What We Can Learn From Previous Clinical Trials
28. Effects of different urodynamic characteristics on therapeutic outcomes of overactive bladder medication in a real-life clinical practice.
29. Potential urine biomarkers in bladder outlet obstruction-related detrusor underactivity.
30. Neurotoxin Versus Neuromodulation for the Treatment of Refractory Overactive Bladder Syndrome
31. Treatment Strategies for Neurogenic Voiding Dysfunction
32. Pathogenesis evidence from human and animal models of detrusor underactivity.
33. Comparison of the Therapeutic Effects of Urethral Injections of 50 and 100 Units of Botulinum A Toxin for Voiding Dysfunction
34. Ultrastructural changes in the underactive bladder
35. Recurrent urinary tract infection in women and overactive bladder – Is there a relationship?
36. Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?
37. Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder
38. Role of videourodynamic study in precision diagnosis and treatment for lower urinary tract dysfunction
39. Precision medicine in the diagnosis and treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia
40. Ultrastructural changes in the underactive bladder.
41. Therapeutic potential of intravesical injections of platelet-rich plasma in the treatment of lower urinary tract disorders due to regenerative deficiency
42. Role of videourodynamic study in precision diagnosis and treatment for lower urinary tract dysfunction.
43. Precision medicine in the diagnosis and treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
44. Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder.
45. Individualizing medical treatment of overactive bladder
46. Recent advances in recurrent urinary tract infection from pathogenesis and biomarkers to prevention
47. Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts
48. Current pharmacological and surgical treatment of underactive bladder
49. Current consensus and controversy on the treatment of male lower urinary tract symptoms/benign prostatic hyperplasia
50. Recent research on the role of urodynamic study in the diagnosis and treatment of male lower urinary tract symptoms and urinary incontinence
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.